Allarity Therapeutics, Inc. (ALLR)
1.25
-0.01
(-0.95%)
USD |
NASDAQ |
Sep 10, 10:35
Allarity Therapeutics Enterprise Value : 15.38M for Sept. 9, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 09, 2026 | 15.38M |
| September 08, 2026 | 15.19M |
| September 04, 2026 | 17.90M |
| September 03, 2026 | 18.06M |
| September 02, 2026 | 17.74M |
| September 01, 2026 | 17.90M |
| August 31, 2026 | 17.74M |
| August 28, 2026 | 17.74M |
| August 27, 2026 | 17.26M |
| August 26, 2026 | 16.63M |
| August 25, 2026 | 16.47M |
| August 24, 2026 | 17.42M |
| August 21, 2026 | 17.90M |
| August 20, 2026 | 18.06M |
| August 19, 2026 | 18.06M |
| August 18, 2026 | 16.78M |
| August 17, 2026 | 16.63M |
| August 14, 2026 | 17.10M |
| August 13, 2026 | 16.94M |
| August 12, 2026 | 17.58M |
| August 11, 2026 | 18.06M |
| August 10, 2026 | 17.74M |
| August 07, 2026 | 17.42M |
| August 06, 2026 | 17.58M |
| August 05, 2026 | 16.47M |
| Date | Value |
|---|---|
| August 04, 2026 | 16.15M |
| August 03, 2026 | 15.51M |
| July 31, 2026 | 14.56M |
| July 30, 2026 | 14.88M |
| July 29, 2026 | 13.76M |
| July 28, 2026 | 14.08M |
| July 27, 2026 | 14.88M |
| July 24, 2026 | 14.24M |
| July 23, 2026 | 14.72M |
| July 22, 2026 | 15.67M |
| July 21, 2026 | 14.72M |
| July 20, 2026 | 13.92M |
| July 17, 2026 | 14.24M |
| July 16, 2026 | 13.92M |
| July 15, 2026 | 14.08M |
| July 14, 2026 | 13.76M |
| July 13, 2026 | 13.28M |
| July 10, 2026 | 13.84M |
| July 09, 2026 | 14.40M |
| July 08, 2026 | 13.76M |
| July 07, 2026 | 13.28M |
| July 06, 2026 | 14.40M |
| July 02, 2026 | 16.15M |
| July 01, 2026 | 16.47M |
| June 30, 2026 | 15.83M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 3.882B |
| Alnylam Pharmaceuticals, Inc. | 34.18B |
| Anika Therapeutics, Inc. | 266.28M |
| Savara, Inc. | 969.61M |
| Vericel Corp. | 1.927B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.405M |
| Total Expenses (Quarterly) | 3.405M |
| EPS Diluted (Quarterly) | -0.214 |
| Earnings Yield | -62.91% |
| Normalized Earnings Yield | -62.46 |